The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
Humans collect several species of Russula for food. There is a cultural divide toward interpretation of Russula edibility. In general, North American field guides tend to list mostly non-edible species and advise caution when consuming any member of the genus. In contrast, European field guides have a more favorable opinion and list more edible species. In the Pacific Northwest region of North America, only Russula brevipes parasitized with Hypomyces lactifluorum—known as lobster mushroom—is collected commercially. Several Russula species are sold in the markets of Izta-Popo Zoquiapan National Park (central Mexico): R. brevipes, R. cyanoxantha, R. mexicana and R. olivacea. In Tlaxcala, wild species sold in market include R. alutacea, R. cyanoxantha, R. delica, R. mariae, R. olivacea, R. romagnesia, and R. xerampelina. In Madagascar, species collected from introduced eucalypt forests include Russula madecassense, Russula prolifica, and several other species of minor importance, including some that have not yet been officially described. Russula is the most commonly consumed and economically important mushroom genus in Madagascar, particularly Russula prolifica and Russula edulis. This and other edible Russula are typically stripped of their cap cuticle before selling to make them more similar in appearance to the Agaricus bisporus. In Tanzania, Russula cellulata and Russula ciliata are sometimes used as food. Russula cyanoxantha is a popular edible throughout Asia, Europe, and the Pacific.
Kardashev first outlined his scale in a paper presented at the 1964 conference that communicated findings on BS-29-76, the Byurakan Conference in the Armenian SSR, which reviewed the Soviet radio astronomy space listening program. The paper was titled "Передача информации внеземными цивилизациями" or Transmission of Information by Extraterrestrial Civilizations. The paper was published in 1964 first in Russian in the March–April issue of the Astronomicheskii Zhurnal, then in English in the September–October 1964 issue of the Soviet Astronomical Journal. In it, the scientist presents a calculation of the evolution of the power needs of humanity. Assuming that overall human power use will continue to increase, he calculates that the rate of energy consumption will cross specific mileposts. Kardashev proposed a typology of technological civilizations based on the evolutive attainment of the three power harnessing mileposts he described. A civilization known as "Type I" has achieved a technological level close to the one attained on Earth at the time Kardashev's article was submitted (December 1963), with a rate of energy consumption evaluated at about 4×1012 watts (W). A civilization known as "Type II" would surpass the first by fourteen orders of magnitude, matching the entire power emitted by the Sun in about 3,200 years, i.e., Earth's home star's "output" at that time, predicted at 4×1026 W.
=== Genetically modified food === In 2015, Ayyadurai published a paper that applied systems biology, which uses mathematical modeling, to predict the chemical composition of genetically modified (GM) soybeans, and whether or not they were substantially equivalent to unmodified soybeans. The paper claimed that GM soybeans have lower levels of the antioxidant glutathione and higher levels of carcinogenic formaldehyde, making the modified soybean substantially different, contrary to previous safety assessments. Shortly after publication, Ayyadurai embarked on a speaking tour of the U.S. At the National Press Club, he said that genetic modification had "fundamentally modified the metabolic system of the soy", disrupting the "beautiful way of detoxifying [formaldehyde]" present in non-GM soy. The European Food Safety Agency evaluated the paper and determined that "the author's conclusions are not supported" due to the lack of information on the input into the model, the fact that the model was not validated and because no measurements of soybeans were made to establish whether GM soy actually contained elevated levels of formaldehyde. Plant scientist Kevin Folta noted that there was "no evidence ever published ... that shows a difference in formaldehyde between GM and non-GM varieties". Ayyadurai later cited the study as evidence of a lack of safety standards for GM foods and bet Monsanto a $10 million building if they could prove that they were safe.
Sources: en.wikipedia.org
In France, Olivier Besancenot, the Revolutionary Communist League candidate in the 2007 presidential election, received 1,498,581 votes (4.08%), double that of the candidate from the French Communist Party candidate. The party abolished itself in 2009 to initiate a broad anti-capitalist movement within a new party called the New Anticapitalist Party, whose stated aim is to "build a new socialist, democratic perspective for the twenty-first century." In Germany, The Left was founded in 2007 out of a merger of the Party of Democratic Socialism (PDS) and the Labour and Social Justice – The Electoral Alternative (WASG), a breakaway faction from the Social Democratic Party of Germany (SPD) which rejected then-SPD leader and German Chancellor Gerhard Schröder for his Third Way policies. According to Kate Hudon, these parties adopted policies to appeal to democratic socialists, greens, feminists and pacifists. Former SPD chairman Oskar Lafontaine has noted that the founding of The Left in Germany has resulted in emulation in other countries, with several Left parties being founded in Greece, Portugal, Netherlands and Syria. Lafontaine claims that a de facto British Left movement exists, identifying the Green Party of England and Wales as holding similar values. Nonetheless, a democratic socialist faction remains within the SPD.
Sexual medicine is concerned with diagnosing, assessing and treating all disorders related to sexuality. Sports medicine deals with the treatment and prevention and rehabilitation of sports/exercise injuries such as muscle spasms, muscle tears, injuries to ligaments (ligament tears or ruptures) and their repair in athletes, amateur and professional. Therapeutics is the field, more commonly referenced in earlier periods of history, of the various remedies that can be used to treat disease and promote health. Travel medicine or emporiatrics deals with health problems of international travelers or travelers across highly different environments. Tropical medicine deals with the prevention and treatment of tropical diseases. It is studied separately in temperate climates where those diseases are quite unfamiliar to medical practitioners and their local clinical needs. Urgent care focuses on delivery of unscheduled, walk-in care outside of the hospital emergency department for injuries and illnesses that are not severe enough to require care in an emergency department. In some jurisdictions this function is combined with the emergency department. Veterinary medicine; veterinarians apply similar techniques as physicians to the care of non-human animals. Wilderness medicine entails the practice of medicine in the wild, where conventional medical facilities may not be available.
Chemical synthesis (chemical combination) is the artificial execution of chemical reactions to obtain one or more products. This occurs by physical and chemical manipulations, usually involving one or more reactions. In modern laboratory uses, the process is reproducible and reliable. A chemical synthesis involves one or more compounds (known as reagents or reactants) that will experience a transformation under certain conditions. Various reaction types can be applied to formulate a desired product. Many reactions require some form of processing ("work-up") or purification procedure to isolate the final product. The amount produced by chemical synthesis is known as the reaction yield. Typically, yields are expressed as a mass in grams (in a laboratory setting) or as a percentage of the total theoretical quantity that could be produced based on the limiting reagent. A side reaction is an unwanted chemical reaction that can reduce the desired yield. The word synthesis was used first in a chemical context by the chemist Hermann Kolbe.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.